Tyrosinkinasen in Weichgewebstumoren

详细信息    查看全文

• 作者：Prof. Dr. T. Kn?sel ; E. Kampmann ; T. Kirchner ; A. Altendorf-Hofmann
• 关键词：VEGFR (vaskul?rer endothelialer Wachstumsfaktor) ; PDGFR (Blutpl?ttchen hervorgegangener Wachstumsfaktor) ; Sarkome ; Immunohistochemie ; überleben ; Vascular endothelial growth factor receptor ; Platelet ; derived growth factor receptor ; Sarcoma ; Immunohistochemistry ; Survival
• 刊名：Der Pathologe
• 出版年：2014
• 出版时间：November 2014
• 年：2014
• 卷：35
• 期：2-supp
• 页码：198-201
• 全文大小：381 KB
• 参考文献：1. Abdeen, (2009) Cancer 115: pp. 5243 CrossRef
  2. Fletcher CDM, World Health Organization, International Agency for Research on Cancer (2013) WHO classification of tumours of soft tissue and bone. IARC Press, Lyon
  3. Folkman, (1972) Ann Surg 175: pp. 409 CrossRef
  4. Fredriksson, (2004) Cytokine Growth Factor Rev 15: pp. 197 CrossRef
  5. Gacche, (2014) Biochim Biophys Acta 1846: pp. 161
  6. Hamidov, (2011) J Clin Pathol 64: pp. 990 CrossRef
  7. Hanahan, (2011) Cell 144: pp. 646 CrossRef
  8. Issels, (2010) Lancet Oncol 11: pp. 561 CrossRef
  9. Kilvaer, (2014) BMC Clin Pathol 14: pp. 5 CrossRef
  10. Kilvaer, (2010) PLoS One 5: pp. e15368 CrossRef
  11. Knosel, (2014) J Clin Pathol 67: pp. 592 CrossRef
  12. Knosel, (2005) Neoplasia 7: pp. 741 CrossRef
  13. Knosel, (2010) Eur J Cancer 46: pp. 1170 CrossRef
  14. Ostman, (2004) Cytokine Growth Factor Rev 15: pp. 275 CrossRef
  15. Ranieri, (2014) Crit Rev Oncol Hematol 89: pp. 322 CrossRef
  16. Sorbye, (2012) PLoS One 7: pp. e47068 CrossRef
  17. Tammela, (2005) Cardiovasc Res 65: pp. 550 CrossRef
  18. Van, (2012) Lancet 379: pp. 1879 CrossRef
  19. Yonemori, (2011) Ann Surg Oncol 18: pp. 2841 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pathology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1963

文摘

The development of therapeutic agents that specifically target the molecular alterations critical for tumorigenesis has a tremendous impact on the management of cancer patients. The successful treatment of advanced gastrointestinal stromal tumors (GIST) with receptor tyrosine kinase (RTK) inhibitors has raised the hope that other malignancies could also benefit from a similar treatment. Tyrosine kinase receptors are promising targets for personalized medicine and new drugs are currently in phase 2 and phase 3 clinical trials. We analyzed a large cohort of soft tissue sarcomas for different tyrosine kinase receptors and correlated the results with clinicopathological parameters. A total of 275 soft tissue sarcomas from the Ludwig-Maximilians University (LMU) were revisited and catagorized according to the current World Health Organization (WHO) classification system. Different entities showed distinct survival curves in 10-year long-term survival. Furthermore, different subtypes of sarcomas showed distinct expression profiles at the protein level. The expression of vascular endothelial growth factor (VEGF) receptors is associated with tumor progression. Due to the fact that not all patients respond to RTK inhibitor therapy, protein signatures should be evaluated before targeting therapy to give a rationale for a viable personalized therapy.